Clene Inc. (CLNN) stock
CLNNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$3.52+0.02 (+0.57%)
Close on Nov 20, 2026Market cap $45.23MP/E –Yield –
Clene gross profit
Gross profit is revenue minus the direct cost of the goods and services sold.
Clene's gross profit for the twelve months ending Jun 30, 2026 was $138.00K, down 40.0% year over year. For fiscal 2025 it was $157.00K, down 42.3% from the year before. The highest annual figure on record is $533.00K in fiscal 2023.
Annual gross profit
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $157.00K | -42.3% |
| FY2024 | Dec 31, 2024 | $272.00K | -49.0% |
| FY2023 | Dec 31, 2023 | $533.00K | +19.2% |
| FY2022 | Dec 31, 2022 | $447.00K | +3.0% |
| FY2021 | Dec 31, 2021 | $434.00K | – |
Quarterly gross profit
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $54.00K | +100.0% |
| Q1 FY2026 | Mar 31, 2026 | $15.00K | -75.4% |
| Q4 FY2025 | Dec 31, 2025 | $54.00K | -26.0% |
| Q3 FY2025 | Sep 30, 2025 | $15.00K | -78.3% |
| Q2 FY2025 | Jun 30, 2025 | $27.00K | -63.0% |
| Q1 FY2025 | Mar 31, 2025 | $61.00K | +7.0% |
| Q4 FY2024 | Dec 31, 2024 | $73.00K | -44.7% |
| Q3 FY2024 | Sep 30, 2024 | $69.00K | -28.1% |
| Q2 FY2024 | Jun 30, 2024 | $73.00K | -64.0% |
| Q1 FY2024 | Mar 31, 2024 | $57.00K | -44.1% |
| Q4 FY2023 | Dec 31, 2023 | $132.00K | +277.1% |
| Q3 FY2023 | Sep 30, 2023 | $96.00K | +220.0% |
| Q2 FY2023 | Jun 30, 2023 | $203.00K | +111.5% |
| Q1 FY2023 | Mar 31, 2023 | $102.00K | – |
| Q2 FY2022 | Jun 30, 2022 | $35.00K | -64.3% |
| Q1 FY2022 | Mar 31, 2022 | $30.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $96.00K | – |
| Q2 FY2021 | Jun 30, 2021 | -$354.00K | – |
| Q3 FY2020 | Sep 30, 2020 | $98.00K | – |
See a number that looks wrong?